Summary
64.96 -0.01(-0.02%)05/16/2024
Alpine Immune Sciences Inc (ALPN)
Alpine Immune Sciences Inc (ALPN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.06 | 0.08 | 67.77 | 138.52 | 413.42 | 764.17 | 86.50 | 806.83 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 64.64 | |
| Open | 64.60 | |
| High | 64.67 | |
| Low | 64.56 | |
| Volume | 1,332,282 | |
| Change | 0.04 | |
| Change % | 0.06 | |
| Avg Volume (20 Days) | 2,112,680 | |
| Volume/Avg Volume (20 Days) Ratio | 0.63 | |
| 52 Week Range | 7.25 - 64.72 | |
| Price vs 52 Week High | -0.12% | |
| Price vs 52 Week Low | 791.59% | |
| Range | 0.06 | |
| Gap Up/Down | -0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,457 | |
| EBIDTA | -48,231,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 20.67 | |
| Book Value | 4.2040 | |
| Earnings Per Share | -1.7230 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | -0.3300 | |
| EPS Estimate Current Year | -1.7300 | |
| EPS Estimate Next Year | -1.5500 | |
| Diluted EPS (TTM) | -1.7230 | |
| Revenues | ||
| Profit Marging | -1.6903 | |
| Operating Marging (TTM) | -1.6674 | |
| Return on asset (TTM) | -0.1321 | |
| Return on equity (TTM) | -0.4363 | |
| Revenue TTM | 24,556,000 | |
| Revenue per share TTM | 1.0200 | |
| Quarterly Revenue Growth (YOY) | 3.4520 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -17,850,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.0404 | |
| Revenue Enterprise Value | 8.7110 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 29,220,200 | |
| Shares Float | 10,041,513 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 26.56 | |
| Institutions (%) | 52.61 | |
05/02 11:05 EST - zacks.com
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/26 16:13 EST - businesswire.com
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alpine Immune Sciences, Inc. (NasdaqGM: ALPN) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Alpine will receive $65.00 in cash for each share of Alpine that they own. KSF is seeking to determine whether this consideration and the process t.
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alpine Immune Sciences, Inc. (NasdaqGM: ALPN) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Alpine will receive $65.00 in cash for each share of Alpine that they own. KSF is seeking to determine whether this consideration and the process t.
04/17 19:50 EST - prnewswire.com
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
NEW YORK , April 17, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc..
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN
NEW YORK , April 17, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc..
04/15 15:43 EST - investorplace.com
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
04/13 05:29 EST - fool.com
Could This Stock Be the Next Biotech Buyout?
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors as Vera Therapeutics' candidate.
Could This Stock Be the Next Biotech Buyout?
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors as Vera Therapeutics' candidate.
04/12 13:41 EST - zacks.com
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
04/11 13:41 EST - schaeffersresearch.com
2 Biotech Stocks Driving the Nasdaq Today
The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.
2 Biotech Stocks Driving the Nasdaq Today
The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.
04/11 10:46 EST - barrons.com
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
The acquisition is a bet on a drug under development to treat the kidney condition IgA nephropathy.
Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
The acquisition is a bet on a drug under development to treat the kidney condition IgA nephropathy.
04/11 10:36 EST - investors.com
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.
04/11 09:47 EST - investorplace.com
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Drug maker Alpine Immune Sciences (NASDAQ: ALPN ) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ: VRTX ) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial.
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Drug maker Alpine Immune Sciences (NASDAQ: ALPN ) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ: VRTX ) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial.
04/11 09:23 EST - invezz.com
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?
04/11 08:06 EST - marketwatch.com
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
04/11 07:16 EST - proactiveinvestors.com
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.
04/10 22:45 EST - investopedia.com
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
04/10 21:50 EST - prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
MILWAUKEE , April 10, 2024 /PRNewswire/ -- Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vertex. Click here to learn how to join the https://www.ademilaw.com/case/alpine-immune-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
MILWAUKEE , April 10, 2024 /PRNewswire/ -- Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vertex. Click here to learn how to join the https://www.ademilaw.com/case/alpine-immune-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
04/10 20:16 EST - geekwire.com
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
04/10 20:08 EST - businesswire.com
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders. Halper Sadeh encourages Alpine shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whe.
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders. Halper Sadeh encourages Alpine shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whe.